Please login to the form below

Not currently logged in
Email:
Password:

Three cancer immunotherapies amongst new CHMP approvals

BMS’ Evotaz also amongst eight new medicine recommendations

EU flag 

Keytruda, Nivolumab and Unituxin are amongst eight new medicines recommended for approval at this month's meeting of the Committee for Medicinal Products for Human Use (CHMP).

Merck's Keytruda (pembrolizumab) has been granted positive opinion to treat advanced melanoma, news that will further please the company following a head-to-head trial with BMS' Yervoy where it outperformed the world's biggest selling melanoma drug.

Nivolumab BMS (nivolumab) received positive opinion to treat adults with squamous non-small lung cancer (NSCLC), while Unituxin (dinutiximab) was given the nod for the treatment of high-risk neuroblastoma, a cancer that is most common in young children.

Further recommendations

Away from immunotherapies, the Committee gave marketing authorisation for Repatha (evolocumab), a first-in-class treatment to lower high levels of cholesterol in the blood of patients where statins are ineffective or who cannot take statins.

Repatha is the first monoclonal antibody in this therapeutic area and is additionally recommended to treat homozygous familial hypercholesterolaemia, a rare inherited disease.

The CHMP also recommended BMS' Evotaz (atazanavir/cobicistat) for HIV-1 infected adults without known mutations associated with resistance to atazanavir, further good news for the company following the FDA's approval for the same indication earlier this year.

Omidria (phenylephrine/ketorolac) received a positive opinion from the Committee for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.

Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised anxiety disorder.

Article by
Kirstie Pickering

27th May 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics